RANITIDINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ranitidine, and what generic alternatives are available?
Ranitidine is a drug marketed by Ajanta Pharma Ltd, Appco, Aurobindo Pharma, Dr Reddys Labs Ltd, Novitium Pharma, Rising, Sandoz, Teva, Bedford, Hikma, Mylan Labs Ltd, Zydus Pharms Usa Inc, Actavis Mid Atlantic, Amneal Pharms, Apotex Inc, Epic Pharma Llc, Lannett Co Inc, Nostrum Labs Inc, Pharm Assoc, Ranbaxy, Sun Pharma Canada, Tolmar, Torrent, Wockhardt, Amneal Pharms Ny, Ani Pharms, Apotex, Boehringer Ingelheim, Contract Pharmacal, Dr Reddys Labs Inc, Glenmark Pharms, Granules, Heritage Pharma Avet, Mpp Pharma, Mylan, Perrigo, Perrigo R And D, Ph Health, Pharmobedient, Strides Pharma, Sun Pharm Inds Ltd, Thinq Pharm-cro Pvt, Vkt Pharma, Watson Labs, and Wockhardt Ltd. and is included in seventy-five NDAs.
The generic ingredient in RANITIDINE is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ranitidine
A generic version of RANITIDINE was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RANITIDINE?
- What are the global sales for RANITIDINE?
- What is Average Wholesale Price for RANITIDINE?
Summary for RANITIDINE
| US Patents: | 0 |
| Applicants: | 45 |
| NDAs: | 75 |
| Drug Prices: | Drug price information for RANITIDINE |
| DailyMed Link: | RANITIDINE at DailyMed |
Recent Clinical Trials for RANITIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cairo University | NA |
| Beijing Wehand-Bio Pharmaceutical Co., Ltd | PHASE1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | PHASE1 |
